IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding

DOI PDF 被引用文献2件
  • David Ternant
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Christophe Arnoult
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Martine Pugnière
    ‡INSERM, U1194, Institut de Recherche en Cancérologie de Montpellier, Université de Montpellier; Montpellier F-34298, France;
  • Christine Dhommée
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Daniel Drocourt
    §InvivoGen, Toulouse F-31400, France;
  • Eric Perouzel
    §InvivoGen, Toulouse F-31400, France;
  • Christophe Passot
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Nadine Baroukh
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Denis Mulleman
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Gérard Tiraby
    §InvivoGen, Toulouse F-31400, France;
  • Hervé Watier
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Gilles Paintaud
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;
  • Valérie Gouilleux-Gruart
    *Université François Rabelais de Tours, CNRS UMR7292, Tours F-37032, France;

説明

<jats:title>Abstract</jats:title> <jats:p>Because IgG1 allotypes might have different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondyloarthritis patients. Infliximab was found to have a shorter half-life in patients homozygous for the G1m17,1 allotypes than in those carrying the G1m3 with no G1m1 (G1m3,-1) allotype. Because the neonatal FcR (FcRn) is involved in the pharmacokinetics of mAbs, the interaction of different IgG1 allotypes with FcRn was examined using cellular assays and surface plasmon resonance. G1m17,1 mAbs, such as infliximab and rituximab, were shown to bind more efficiently to FcRn and to be transcytosed better than the G1m3,-1 mAb cetuximab, which explains why infliximab is a better competitor for endogenous IgG1 in G1m3,-1 allotype–bearing patients. A set of four allotype variants of adalimumab (G1m17,1; G1m17,-1; G1m3,1; and G1m3,-1) was also tested for its binding to FcRn, revealing that the G1m3,1 variant, not present in commercial mAbs, binds more efficiently to FcRn and is transcytosed better than the other three variants, all of which are found in therapeutic mAbs.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ